Oxford BioDynamics (LON:OBD) Hits New 52-Week Low – Time to Sell?

Oxford BioDynamics Plc (LON:OBD) shares reached a new 52-week low on Tuesday . The stock traded as low as GBX 0.19 and last traded at GBX 0.20, with a volume of 21527340 shares traded. The stock had previously closed at GBX 0.20.

Oxford BioDynamics Trading Up 5.0%

The company has a market capitalization of £9.01 million, a P/E ratio of -0.26 and a beta of 0.42. The company has a debt-to-equity ratio of 457.97, a current ratio of 0.88 and a quick ratio of 2.80. The business’s 50-day moving average price is GBX 0.26 and its two-hundred day moving average price is GBX 0.31.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.